Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 14/20 | 0.66 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | GABRP | O00591 | 1/20 | 0.48 |
| ▸ | GABRD | O14764 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | KLK3 | P07288 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.48 |
| ▸ | GABRE | P78334 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17940955 | 0.97 | AR (0.62) | ARABCG2 | |
| SCHEMBL2633034 | 0.90 | AR (0.67) | ARABCG2 | |
| SCHEMBL7034214 | 0.87 | AR (0.59) | ARABCG2GABRPGABRDNR1I2 | |
| SCHEMBL17519923 | 0.87 | AR (0.63) | AR | |
| SCHEMBL17941155 | 0.86 | AR (0.61) | ARABCG2GABRPGABRDNR1I2 | |
| SCHEMBL17940963 | 0.86 | AR (0.50) | AR | |
| SCHEMBL15506546 | 0.86 | AR (0.66) | ARABCG2GABRPGABRDNR1I2 | |
| SCHEMBL30893456 | 0.85 | AR (0.61) | ARABCG2 | |
| SCHEMBL5251869 | 0.85 | AR (0.82) | ARABCG2 | |
| SCHEMBL17941172 | 0.84 | AR (0.57) | ARABCG2GABRPGABRDNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12569464-B2 | Protein-protein interaction inducing technology | ARVINAS OPERATIONS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12312316-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4509184-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20250034096-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-3526202-B1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2025-01-08 | — | — | EP | disclosed |
| US-12077509-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-11964945-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-11952347-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240059686-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. (US) | 2024-02-22 | — | — | US | disclosed |
| EP-3247708-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR | Arvinas, Inc. (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2017-11-16 | — | — | US | disclosed |
| WO-2017176708-A1 | PROTEIN-PROTEIN INTERACTION INDUCING TECHNOLOGY | Arvinas, Inc. (US) | 2017-10-12 | — | — | WO | disclosed |
| US-20170281784-A1 | PROTEIN-PROTEIN INTERACTION INDUCING TECHNOLOGY | ARVINAS OPERATIONS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170008904-A1 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2017-01-12 | — | — | US | disclosed |
| WO-2016118666-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR | Arvinas, Inc. (US) | 2016-07-28 | — | — | WO | disclosed |
| US-20160214972-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2016-07-28 | — | — | US | disclosed |
| WO-2016118666-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR | Arvinas, Inc. (US) | 2016-07-28 | — | — | WO | disclosed |
| US-20160214972-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281784-A1 | PROTEIN-PROTEIN INTERACTION INDUCING TECHNOLOGY | HSPBP1, PEBP1, PMAIP1 | AR 4151/4885ABCG2 2239/4885GABRP 1281/4885 |
| US-20160214972-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ESRRA, MDM2 | AR 1/4885ABCG2 759/4885GABRP 2104/4885 |
| US-20170008904-A1 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, XIAP, TP53 | AR 2454/4885ABCG2 1980/4885GABRP 3520/4885 |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, MDM2, ESRRA | AR 1/4885ABCG2 688/4885GABRP 1937/4885 |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | MDM2, UBR4, UBE3A | AR 2199/4885ABCG2 1149/4885GABRP 2364/4885 |
| US-12312316-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, MDM2, ESRRA | AR 1/4885ABCG2 688/4885GABRP 1937/4885 |
| US-20240059686-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR | AR, VHL, MDM2 | AR 1/4885ABCG2 773/4885GABRP 2123/4885 |
| US-11964945-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | AR 1/4885ABCG2 1034/4885GABRP 1049/4885 |
| US-11952347-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | AR 1/4885ABCG2 1009/4885GABRP 1066/4885 |
| US-12077509-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | AR 1/4885ABCG2 1009/4885GABRP 1066/4885 |
| US-12569464-B2 | Protein-protein interaction inducing technology | STUB1, MDM2, XIAP | AR 3124/4885ABCG2 2467/4885GABRP 1741/4885 |
| US-20250034096-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | AR 1/4885ABCG2 1009/4885GABRP 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.